Viewing Study NCT05847569


Ignite Creation Date: 2025-12-24 @ 11:09 PM
Ignite Modification Date: 2026-01-02 @ 3:32 AM
Study NCT ID: NCT05847569
Status: RECRUITING
Last Update Posted: 2025-06-17
First Post: 2023-04-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Sponsor: Mayo Clinic
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module